Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
GBT launches ACCEL grants program to improve access to care for people with Sickle cell diseaseGlobal Blood Therapeutics, Inc. (GBT) to...
-
Onyinye Onyekwere, MDDr. Onyinye Onyekwere is a pediatric hem...
-
Donald Rucknagel, MD, PhDDr. Rucknagel pioneered the use of incen...
-
Risk Factors Associated With Increased Emergency Department Utilization in Patients With Sickle Cell Disease: A Syst...Sickle cell disease (SCD), a genetic dis...
-
A systematic review of the literature for severity predictors in pediatric sickle cell anemia patientsBackground: All patients with HbSS (SCA)...
-
Foundation For Sickle Cell Disease ResearchThe Foundation for Sickle Cell Disease R...
-
UConn Health / New England Sickle Cell InstituteThe New England Sickle Cell Institute at...
